Myxomatous degeneration: Difference between revisions

Jump to navigation Jump to search
(Have added text under all the headings)
Line 69: Line 69:


== Natural History, Complications and Prognosis==
== Natural History, Complications and Prognosis==
*The majority of patients with [disease name] remain asymptomatic for [duration/years].  
*The majority of patients with Myxomatous degeneration of Mitral Valve are asymptomatic.
*Early clinical features include presence of a heart murmur.
*Early clinical features include presence of a heart murmur.
*If left untreated,about 10% of patients with Myxomatous degeneration of Mitral Valve may progress to develop severe Mitral regurgitation requiring surgical repair of the valve.
*If left untreated,about 10% of patients with Myxomatous degeneration of Mitral Valve may progress to develop severe Mitral regurgitation requiring surgical repair of the valve.

Revision as of 17:06, 15 June 2020

WikiDoc Resources for Myxomatous degeneration

Articles

Most recent articles on Myxomatous degeneration

Most cited articles on Myxomatous degeneration

Review articles on Myxomatous degeneration

Articles on Myxomatous degeneration in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Myxomatous degeneration

Images of Myxomatous degeneration

Photos of Myxomatous degeneration

Podcasts & MP3s on Myxomatous degeneration

Videos on Myxomatous degeneration

Evidence Based Medicine

Cochrane Collaboration on Myxomatous degeneration

Bandolier on Myxomatous degeneration

TRIP on Myxomatous degeneration

Clinical Trials

Ongoing Trials on Myxomatous degeneration at Clinical Trials.gov

Trial results on Myxomatous degeneration

Clinical Trials on Myxomatous degeneration at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Myxomatous degeneration

NICE Guidance on Myxomatous degeneration

NHS PRODIGY Guidance

FDA on Myxomatous degeneration

CDC on Myxomatous degeneration

Books

Books on Myxomatous degeneration

News

Myxomatous degeneration in the news

Be alerted to news on Myxomatous degeneration

News trends on Myxomatous degeneration

Commentary

Blogs on Myxomatous degeneration

Definitions

Definitions of Myxomatous degeneration

Patient Resources / Community

Patient resources on Myxomatous degeneration

Discussion groups on Myxomatous degeneration

Patient Handouts on Myxomatous degeneration

Directions to Hospitals Treating Myxomatous degeneration

Risk calculators and risk factors for Myxomatous degeneration

Healthcare Provider Resources

Symptoms of Myxomatous degeneration

Causes & Risk Factors for Myxomatous degeneration

Diagnostic studies for Myxomatous degeneration

Treatment of Myxomatous degeneration

Continuing Medical Education (CME)

CME Programs on Myxomatous degeneration

International

Myxomatous degeneration en Espanol

Myxomatous degeneration en Francais

Business

Myxomatous degeneration in the Marketplace

Patents on Myxomatous degeneration

Experimental / Informatics

List of terms related to Myxomatous degeneration

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Overivew

Myxomatous degeneration refers to a pathological weakening of connective tissue. The term is most often used in the context of Mitral valve prolapse, which is known more technically as "Myxomatous degeneration of the mitral valve." [1] It can also be used in reference to degeneration of the aortic valve.

Pathophysiology

The degeneration occurs in conjunction with an accumulation of dermatan sulfate, a glycosaminoglycan, within the connective tissue matrix of the valve. The exact mechanism is unknown.

In many cases, the degeneration is limited to the mitral valve and follows a benign course. When associated with systemic diseases, like Marfan syndrome, the degeneration is more extensive and involves other heart valves. The valves can become sufficiently distorted to cause insufficiency and regurgitation.

Deposition of excessive proteoglycans causes widening of the fibrosa, which extends towards basal aspects and also tends to involve the annulus and chords, which further leads to loss of collagen an elastic tissue.

Historical Perspective

  • Myxomatous Mitral Valve disease was first reported by Delabere Blaine in 1817 in dogs.
  • Myxomatous Degeneration of Mitral Valve is a gentic abnormality mapped to Xq28 gene.

Classification

  • Myxomatous degeneration may be classified as:
  • Primary
  • Secondary Whitney in1967 classified Myxomatous Mitral Valve Disease into 4 types based on the structures involved-
  • Type I,II- Small nodular thickening of mitral leaflets without chordae tendinae involvement
  • Type III-Severe thickening and ballooning of valve cusps
  • Type IV- Chordae tendinae thickening and Occasional rupture

Pathophysiology

  • The pathogenesis of Myxomatous mitral valve degeneration is characterized by Valvular or chordal degeneration with excesssive systolic movement of leaflet defined by a prolapse in Left atrium >/2mm.
  • It can affect one or both leaflets and can affect one or multiple scallops.
  • Degeneration of Mitral valve is divided into two phenotypes:
    1. Fibro Elastic Deficiency:
      • localised to one segment.
      • involves ruptured chords.
      • Histologically- Myxomatous degeneration
      • Macroscopically- Leaflet redundancy and thickening predominant on the flail segment.
      • Reminder of the valve is thin and translucent.
      • Patients present in older ages.
    2. Diffuse Myxomatous Degeneration:
        • Generalised
        • redundancy and thickening of both leaflets involving multiple segments.
        • Mitral Regurgitation typically predominates in midlate systole.
        • Severeity varies from mild to severe.

Clinical Features:

Patients can be asymptomatic,or can have mild to severe symptoms.

Patients can have heart murmur, cough, dyspnea, signs and symptoms of Congestive Heart Failure, Arrythmias.

Differentiating Myxomatous Mitral Valve Degeneration from other Diseases

  • Myxomatous degeneration of Mitral Valve must be differentiated from other diseases that cause Mitral Valve Regurgiation, such as:
  • Ischemic Injury to Mitral Valve
  • Rheumatic Heart Disease
  • Connective tissue disorder

Epidemiology and Demographics

  • The prevalence of Myxomatous Mitral Valve Degeneration in Canines, increases as age increase, and the prevalence especially in old, small breed dogs is 100%.
  • It affects about 5% of the Human population.

Age and Gender

  • It is more common in Young females.
  • It is frequently symptomatic in males.

Risk Factors

  • Common risk factors in the development of Myxomatous degeneration are Connective tissue disorders like Marfan's Syndrome, Ehlers-Danlos syndrome, and other conditions with collagen abnormalities.

Natural History, Complications and Prognosis

  • The majority of patients with Myxomatous degeneration of Mitral Valve are asymptomatic.
  • Early clinical features include presence of a heart murmur.
  • If left untreated,about 10% of patients with Myxomatous degeneration of Mitral Valve may progress to develop severe Mitral regurgitation requiring surgical repair of the valve.
  • Common complications of Myxomatous degeneration of Mitral Valve include Arrythmias, Congestive Heart Failure,Endocarditis ,rarely Sudden cardiac death.
  • Prognosis is generally good after MItral Valve repair.

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • Myxomatous degeneration of mitral valve can be asymptomatic.
  • Symptoms of Myxomatous degeneration of Mitral valve may include the following:
  • Apical Holosystolic murmur
  • Systolic click to mid lat systolic murmur
  • Cough - due to Heart failure
  • Dyspnea- Pulmonary edema, Pulmonary Hypertension.
  • Syncope- arrythmias

Physical Examination

  • Patients with Myxomatous degeneration of mitral valve ususally present with Mitral Valve prolapse.
  • Physical examination may be remarkable for:
  • Systolic click or mid-late systolic murmur.
  • Apical holosystolic murmur

Laboratory Findings

  • There are no specific laboratory findings associated with Myxomatous degeneration of Mitral valve

Imaging Findings

  • 2D Echocardiography is the imaging modality of choice.
  • Transesophageal Echo- shows Mitral valve prolapse and Mitral valve thickening.

Other Diagnostic Studies

  • Xray Chest- can show cardiomegaly.
  • Electrocardiogram (ECG)- non invasive test, CAn help in detecting arrythmias, Left atrial enlargement, Left Ventricle hypertrophy.
  • CT Scan-non invasive imaging test,Can measure the degree of leaflet displacement and relation between valve leaflets and annulus.
  • MRI- non invasive, can provide information on the severeity of Mitral Regurgitation.

Treatment

Medical Therapy

  • There is no medical therapy for Myxomatous degeneration of Mitral Valve, the mainstay of therapy is supportive care.
  • Diuretics- if symptoms of Heart failure
  • ACE inhibitors
  • β blockers
  • Vasodilators

Surgery

  • Surgery is the mainstay of therapy for Myxomatous degeneration of Mitral Valve.
  • Mitral Valve repair is the preferred surgical technique.
  • Mitral valve repair when compared to replacement improves survival, Left ventricular function, and decreased chance of reoperation.
  • Mitral Valve replacement can also be done.

Prevention

  • There are no primary preventive measures available for Myxomatous degeneration of Mitral Valve.

References

  1. Cotran RS, Kumar V, Fausto N, Nelso F, Robbins SL, Abbas AK. Robbins and Cotran pathologic basis of disease. 7th ed. Elsevier Saunders. St. Louis, Mo 2005 ISBN 0-7216-0187-1


Template:SIB


Template:WikiDoc Sources